Results 251 to 260 of about 735,101 (274)

[Cetuximab improved the poor performance status of a colorectal cancer patient].

Gan to kagaku ryoho. Cancer & chemotherapy, 2015
A 60-year-old man with unresectable colon cancer required treatment for hydronephrosis, acute cholecystitis, and obstructive jaundice before chemotherapy. His performance status (PS) gradually deteriorated to PS 4. Cetuximab monotherapy was initiated instead of intensive chemotherapy.
Hideki, Sakisaka, Takeshi, Kato, Yoshinori, Kagawa, Tomo, Ishida, Yasufumi, Sato, Yoshihiro, Morimoto, Katsunori, Matsushita, Tadayoshi, Hashimoto, Hiroki, Kusama, Kei, Kimura, Yoshiteru, Katsura, Kanae, Nitta, Masatsugu, Okishiro, Atsushi, Takeno, Shin, Nakahira, Hirokazu, Taniguchi, Chiyomi, Egawa, Yutaka, Takeda, Shigeyuki, Tamura   +18 more
openaire   +1 more source

Treatment in patients with glioblastoma multiforme and poor performance status: is it worthwhile?

Radiation medicine, 1998
It has not been ascertained that treatment of glioblastoma multiforme of the brain (GMB) favorably alters the prognosis in patients with poor pretreatment performance status (PPS). We report on 52 patients with GMB and PPS. The mean survival of 43 treated persons was 19 +/- 12 months (95% confidence interval) and of nine untreated individuals, 2 +/- 1 ...
F L, Ampil, A, Nanda, B K, Willis, S, Apple   +3 more
openaire   +1 more source

Management of patients with non-small cell lung cancer and poor performance status

Current Treatment Options in Oncology, 2003
Lung cancer is the leading cause of cancer-related deaths. Non-small cell lung cancer (NSCLC) accounts for approximately 86% of patients with lung cancer. The two most powerful predictors of long-term outcome in patients with NSCLC are the stage and performance status (PS) at diagnosis.
openaire   +2 more sources

Clinical Activity of MET-TKIs in METex14 Skipping NSCLC With Poor Performance Status

Anticancer Research
The mesenchymal-epithelial transition (MET) receptor plays a key role in cell growth and survival. The MET exon 14 (METex14) skipping mutation occurs in 3% to 4% of patients with non-small cell lung cancer (NSCLC) and leads to prolonged MET signaling and oncogenesis. MET tyrosine kinase inhibitors (TKIs), such as tepotinib and capmatinib, are effective
Yoh, Yamaguchi, Tatsuya, Yoshida, Ryoko Inaba, Higashiyama, Ken, Masuda, Yuki, Shinno, Yusuke, Okuma, Yasushi, Goto, Hidehito, Horinouchi, Noboru, Yamamoto, Yuichiro, Ohe   +9 more
openaire   +2 more sources

Lipid lowering therapy in elderly patients with poor performance status

Atherosclerosis, 2022
I. Papakitsou, E. Petrakis, V. Mavrikaki, G. Vougiouklakis, D. Spentzouri, S. Tzalis, A. Matheakakis, A. Tsiavos, K. Vasilopoulos, M. Bargodakis, I. Akoumianakis, P. Ioannou, T. Filippatos   +12 more
openaire   +1 more source

Immunotherapy in lung cancer: effective for patients with poor performance status?

The Lancet Respiratory Medicine, 2020
Joao V, Alessi, Mark M, Awad
openaire   +2 more sources

Frontline immune checkpoint inhibitor-based combination therapy in metastatic renal cell carcinoma patients with poor performance status

European Journal of Cancer, 2023
Lucia Carril-Ajuria, François Cherifi, Claude Linassier   +2 more
exaly  

Rethinking immunotherapy in patients with SCLC with poor performance status

The Lancet Respiratory Medicine
Reguart, Noemi, Hendriks, Lizza E.L.
openaire   +3 more sources

Outcomes of Immune Checkpoint Inhibitors in Patients with Cancer and a Poor Performance Status #445

Journal of Palliative Medicine, 2022
Alyssa Scher, Camilla Melegari, Ramy Sedhom   +2 more
openaire   +2 more sources

First line pembrolizumab for metastatic NSCLC in poor performance status patients

Lung Cancer, 2022
Brian Clark, Rosie Harrand, Lucy Dornan
openaire   +1 more source